2019 OutSmarting Osteosarcoma Funding CLOSED – Check back in April 2020!

The Process:
1. If you wish to apply for the OutSmarting Osteosarcoma Grant, submit your abstract below, deadline for submissions is April 20, 2019.
2. Finalist Meeting will take place at the ASCO Meeting in Chicago in June 1, 2019, MIB Agents Scientific Advisory Board will present all proposals offers their evaluation and the entire selection committee* votes anonymously for the three finalists.
3. Three finalists are then shared with all attendees of the 2019 FACTOR conference to vote for the winner.
4. Winning proposal will be announced on June 20, 2019.
*Attending the finalist selection meeting is open to anyone who raised/donated at least $5,000 to MIB Agents for Osteosarcoma-specific research since July 1, 2018

Applying For The $100,000 OutSmarting Osteosarcoma Grant

Submit Your Abstract

Guidelines: Proposal must benefit the osteosarcoma patient and be a new project or distinct portion of an ongoing larger project for which results can be expected in 12 months. At the completion of 12 months, results must be made available to share – regardless of succeed or fail outcome. The recipient must be available to present work underway and completed at the FACTOR conference in 2020. Grant may not be used for the formation of a new organization, used for planning stages of research or other initiatives, or for any indirect costs. Presentation of check and tour of the facility by MIB Agents is requested.

Please fill out electronic submission form, proposals will be submitted as a layman’s summary and are limited to one page front and back.

Completed RFP will be available for the public to view here on the MIB Agent’s website and through social media. Deadline for submission is April 20, 2019. If you have any questions please email

About the Meeting

By attending this meeting, you can vote for the three finalists that will then be voted on by all the attendees of the 2019 FACTOR conference. The winning proposal will receive $100,000 in osteosarcoma research funding from MIB Agents.

When: June 1, 2019
Where: ASCO Annual Meeting in Chicago, IL
Want to Attend? To receive an invitation to this meeting you must have donated or raised $5,000 or more for Osteosarcoma Research to MIB Agents since July 1st, 2018. Invitations to the meeting will be sent out in April.
To make your donation today, click HERE or mail your donation to: MIB Agents, PO Box 858, Barnard VT 05031

2018 OutSmarting Osteosarcoma Meeting in Washington DC
2019 OutSmarting Osteosarcoma Meeting in Chicago, IL

OutSmarting Osteosarcoma Past Winners

2018 OutSmarting Osteosarcoma winner, Matteo Trucco, MD of University of Miami, Sylvester Comprehensive Cancer Center
2017 OutSmarting Osteosarcoma winner, Joshua Schiffman, MD of Huntsman Cancer Institute

Scientific Advisory Board

Matteo Trucco, MD

Dr. Matteo Trucco received his training in Pediatric Hematology/Oncology from Johns Hopkins University and the National Cancer Institute and has focused his career primarily on Pediatric Sarcomas and the development of new therapies. As the Director of the Pediatric Phase 1 Program at the University of Miami-Sylvester Comprehensive Cancer Center he seeks to identify novel approaches to treating Pediatric Sarcomas, with a particular interest in targeting sarcomas’ metabolism, their hypoxic areas and sarcoma stem cells. He jumped at the opportunity to help bring together researchers, clinicians, patients and advocates as part of the FACTOR conference to stimulate innovation and collaboration to advance the research and treatment of Osteosarcoma.

Peter Anderson, MD

He graduated summa cum laude from University of Minnesota, then began an MD, PhD program. This was completed at Mt. Sinai School of Medicine and City University of New York (Biochemical Genetics). Anderson then did a combined Internal Medicine/Pediatrics residency at Duke and Fellowship in Peds Heme/Onc/BMT at University of Minnesota – where he had a lab and obtained 3 patents. He then spent 10 years at Mayo (promoted to Professor) and was involved in some innovative osteosarcoma clinical trials including use of samarium. He was at MD Anderson Cancer Center 2005-2014 and tested mifamurtide, anti-IGFR, samarium, and 223Ra against osteosarcoma. Now at Cleveland Clinic, he remains active in patient advocacy and novel approaches to care of patients with sarcomas, especially osteosarcoma.

Ramy Ibrahim, MD

Ramy Ibrahim, MD, is a recognized leader of clinical development in immunotherapy. He helped develop some of the first breakthrough treatments in the field during his tenure at Bristol-Myers Squibb and MedImmune/AstraZeneca. Dr. Ibrahim currently serves as vice president of clinical development at the Parker Institute for Cancer Immunotherapy. Throughout his career, Dr. Ibrahim has been involved with global cancer immunotherapy societies such as the Society of Immunotherapy for Cancer (SITC), Ludwig Institute, the Cancer Research Institute and Cancer Immunotherapy Trials Network (CITN). He is a trained medical oncologist, who conducted bench and clinical immunotherapy research at the cancer vaccine branch of the National Cancer Institute in Bethesda, MD.

Rosandra Kaplan, MD

Dr. Kaplan is a physician scientist who developed the concept of the pre-metastatic niche describing the changes in distant microenvironments in response to a growing tumor that create a niche environment conducive to disseminating tumor cell survival and growth resulting in clinically relevant metastasis. Dr. Kaplan has an active translational research program focusing on developing novel biomarkers and targets of the metastatic microenvironment by understanding the commonalities in mechanisms employed by a cancer cell to generate an entire heterogenous tumor at distant sites and stem cells and their niche to repopulate tissues.

John H. Healey, MD, FACS

Dr. Healey has decades of experience diagnosing and treating sarcomas and benign tumors of the bones and soft tissue. He is an expert in surgery to remove tumors while preserving limbs, and rebuild functional bones and joints with joint replacements and bone transplants. Dr. Healey has a special interest in treating children who have bone cancers (osteosarcoma and Ewing sarcoma). His research involves understanding the molecular biology of sarcoma, developing new ways to deliver chemotherapy to tumors, and improving the durability and function of joint replacements. Dr. Healey has invented and developed four different joint replacement systems and has patented several methods to deliver drugs to tumors and to study cancers in the laboratory. In addition to his role as Chief of the Orthopaedic Service at Memorial Soan-Kettering, he is a Professor of Orthopaedic Surgery at Weill Cornell Medical College. Nationally, Dr. Healey has served as Chair of the Children’s Oncology Group Orthopaedics Section, as President of the International Society of Limb Salvage, President of the Association of Bone and Joint Surgeons, and on the boards of several musculo- skeletal and orthopedic organizations. 


Damon R. Reed, MD

Dr. Damon Reed is the Director of the Adolescent and Young Adult Program at Moffitt, the Medical Director of the Sarcoma Department at Moffitt Cancer Center and an Assistant Professor of Pediatrics at the University of South Florida. He is also an on staff as a specialty physician at All Children’s Hospital in St. Petersburg, FL. He is also the Leader of the Pediatric Cancer Foundation’s pediatric phase I consortium, the Sunshine Project. A graduate of Case Western Reserve University School of Medicine in Cleveland, OH, Dr. Reed served a combined pediatric residency program at Boston Children’s Hospital-Harvard Medical School and Boston Medical Center-Boston University School of Medicine.  He completed his fellowship training in pediatric hematology/oncology at St. Jude Children’s Research Hospital. He received the CWRU Medical Alumni Association Board of Trustees Award for Outstanding Service and Contributions to the School of Medicine and was named to the Alpha Omega Alpha Honor Medical Society. Dr. Reed is a member of several professional associations, including the American Association for Cancer Research, Connective Tissue Oncology Society and American Society of Clinical Oncology. He joined Moffitt in 2008.

Social media & sharing icons powered by UltimatelySocial